Osage University Partners has participated in a $62m series B round for Satsuma Pharmaceuticals, which also featured Shin Nippon Biomedical Laboratories.
Satsuma Pharmaceuticals, a US-based acute migraine treatment developer, obtained $62m in series B funding yesterday from investors including spinout-focused investment firm Osage University Partners.
Wellington Management Company led the round, which also featured contract research firm Shin Nippon Biomedical Laboratories, RA Capital Management, TPG Biotech, Cam Capital, Surveyor, Eventide Asset Management, Cormorant, Lumira Ventures and SBI Investment.
Satsuma, spun out of Shin Nippon Biomedical Laboratories in 2016, is working on a medical device to self-administer a proprietary form…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
